Enzymotec (ENZY) to Release Quarterly Earnings on Tuesday

Enzymotec (NASDAQ:ENZY) is scheduled to announce its earnings results before the market opens on Tuesday, February 20th. Analysts expect the company to announce earnings of $0.08 per share for the quarter.

Enzymotec (NASDAQ:ENZY) last released its quarterly earnings results on Wednesday, November 15th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.03). Enzymotec had a return on equity of 1.24% and a net margin of 2.32%. The firm had revenue of $13.67 million for the quarter, compared to analyst estimates of $14.36 million. On average, analysts expect Enzymotec to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Enzymotec (NASDAQ ENZY) opened at $11.85 on Tuesday. Enzymotec has a 12-month low of $6.30 and a 12-month high of $12.35. The firm has a market capitalization of $277.62, a price-to-earnings ratio of -43.89, a PEG ratio of 3.19 and a beta of 1.22.

An institutional investor recently raised its position in Enzymotec stock. State Street Corp lifted its stake in shares of Enzymotec Ltd (NASDAQ:ENZY) by 1.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,952 shares of the biotechnology company’s stock after acquiring an additional 380 shares during the quarter. State Street Corp owned 0.09% of Enzymotec worth $169,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 15.73% of the company’s stock.

A number of analysts have recently weighed in on the company. Jefferies Group reaffirmed a “hold” rating and set a $11.50 price objective on shares of Enzymotec in a research report on Thursday, October 19th. Zacks Investment Research raised Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. BidaskClub lowered Enzymotec from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Finally, Wells Fargo & Co upped their price objective on Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a research report on Monday, October 30th. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $11.75.

TRADEMARK VIOLATION WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/13/enzymotec-enzy-to-release-quarterly-earnings-on-tuesday.html.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Earnings History for Enzymotec (NASDAQ:ENZY)

Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply